Search Results
You are looking at 1 - 3 of 3 items for
- Author: C Bernard x
- Refine by access: All content x
Search for other papers by SJ Bernard in
Google Scholar
PubMed
Search for other papers by I Yuen in
Google Scholar
PubMed
Search for other papers by C McMillen in
Google Scholar
PubMed
Search for other papers by ME Symonds in
Google Scholar
PubMed
Search for other papers by PC Owens in
Google Scholar
PubMed
Leptin mRNA was measured in adipose tissue of fetal sheep by reverse transcription polymerase chain reaction (RTPCR). Abundance of leptin mRNA relative to b-actin mRNA in fetal perirenal adipose tissue increased (P<0.02) with gestation, being higher at 144 d (0.73 +/- 0. 10, n=5) than at 90-91 d (0.40 +/- 0.08, n=6) or 125 d (0.40 +/- 0. 04, n=5) gestation (term approximately 147- 150 d). There was a positive relationship between relative abundance of leptin mRNA (y) and fetal body weight (x)between 90 and 144 d gestation (r 2 =0.27, P<0.01). The slope of the linear dependence of leptin mRNA on fetal weight was 15-fold greater (P<0.001) at 90-91d (y = 2.81x - 1.1, n=6, r 2 =0.71, P<0.025) than between 125-144 d gestation (y = 0.195x - 0.15, n=16, r 2 =0.39, P<0.01). Thus the leptin synthetic capacity of fetal adipose tissue appears to increase in late gestation but this is accompanied by constraint of its sensitivity to fetal body weight. We hypothesise that leptin synthesis in fetal adipose tissue is related to fetal nutrient supply and growth rate.
Search for other papers by C Ratineau in
Google Scholar
PubMed
Search for other papers by C Roche in
Google Scholar
PubMed
Search for other papers by F Chuzel in
Google Scholar
PubMed
Search for other papers by M Cordier-Bussat in
Google Scholar
PubMed
Search for other papers by M Blanc in
Google Scholar
PubMed
Search for other papers by C Bernard in
Google Scholar
PubMed
Search for other papers by J-C Cuber in
Google Scholar
PubMed
Search for other papers by J-A Chayvialle in
Google Scholar
PubMed
Abstract
The effect of glucocorticoids on the expression of intestinal cholecystokinin (CCK) was investigated both in vivo and in cell culture systems. In vivo, 2-day administration of methylprednisolone to adult male rats induced a decrease in CCK-like immunoreactivity (CCK-LI) and CCK mRNA levels in mucosal extracts. In two CCK-producing cell lines, RIN 1056E and STC-1 of pancreatic and intestinal origin respectively, dexamethasone induced dose-dependent decreases in both CCK-LI and steady-state CCK mRNA levels. The decrease in CCK mRNA was totally prevented by incubation of cells with an excess of RU 38486, a competitive inhibitor for the binding of glucocorticoids to their receptor. Actinomycin D, used to prevent RNA synthesis, did not modify CCK mRNA stability in dexamethasone-pretreated cells as compared with cells not exposed to dexamethasone. When cells were first incubated with actinomycin D, subsequent addition of dexamethasone left the steady-state CCK mRNA levels unaltered in both cell lines. Nuclear run-on assays performed in RIN 1056E cells showed that glucocorticoids decreased the rate of transcription of the CCK gene. In addition, cycloheximide, used to prevent protein synthesis, abolished the inhibitory effects of dexamethasone on steady-state CCK mRNA levels. These results demonstrate that glucocorticoids down-regulate CCK gene expression in the rat intestinal mucosa and in two CCK-producing cell lines. The effect is blocked by a glucocorticoid receptor antagonist. Inhibition of CCK gene expression may result from a decrease in the transcription rate, and probably involves one or several steps that depend on protein synthesis.
Journal of Endocrinology (1996) 151, 137–145
Department of Pediatrics, Department of Medicine, Department of Pediatric Endocrinology, Endocrinology and Metabolism, Developmental Biology and Cancer Programme, Department of Pharmacology and Therapeutics, Center for Reproductive Medicine, Leiden University Medical Center, Leiden, The Netherlands
Search for other papers by Sjoerd D Joustra in
Google Scholar
PubMed
Search for other papers by Onno C Meijer in
Google Scholar
PubMed
Department of Pediatrics, Department of Medicine, Department of Pediatric Endocrinology, Endocrinology and Metabolism, Developmental Biology and Cancer Programme, Department of Pharmacology and Therapeutics, Center for Reproductive Medicine, Leiden University Medical Center, Leiden, The Netherlands
Search for other papers by Charlotte A Heinen in
Google Scholar
PubMed
Search for other papers by Isabel M Mol in
Google Scholar
PubMed
Search for other papers by El Houari Laghmani in
Google Scholar
PubMed
Search for other papers by Rozemarijn M A Sengers in
Google Scholar
PubMed
Search for other papers by Gabriela Carreno in
Google Scholar
PubMed
Search for other papers by A S Paul van Trotsenburg in
Google Scholar
PubMed
Search for other papers by Nienke R Biermasz in
Google Scholar
PubMed
Search for other papers by Daniel J Bernard in
Google Scholar
PubMed
Search for other papers by Jan M Wit in
Google Scholar
PubMed
Search for other papers by Wilma Oostdijk in
Google Scholar
PubMed
Search for other papers by Ans M M van Pelt in
Google Scholar
PubMed
Search for other papers by Geert Hamer in
Google Scholar
PubMed
Search for other papers by Gerry T M Wagenaar in
Google Scholar
PubMed
Loss-of-function mutations in the immunoglobulin superfamily member 1 (IGSF1) gene cause an X-linked syndrome of central hypothyroidism, macroorchidism, variable prolactin and GH deficiency, delayed pubertal testosterone rise, and obesity. To understand the pathophysiology of this syndrome, knowledge on IGSF1's place in normal development is imperative. Therefore, we investigated spatial and temporal protein and mRNA expression of IGSF1 in rats using immunohistochemistry, real-time quantitative PCR (qPCR), and in situ hybridization. We observed high levels of IGSF1 expression in the brain, specifically the embryonic and adult choroid plexus and hypothalamus (principally in glial cells), and in the pituitary gland (PIT1-lineage of GH, TSH, and PRL-producing cells). IGSF1 is also expressed in the embryonic and adult zona glomerulosa of the adrenal gland, islets of Langerhans of the pancreas, and costameres of the heart and skeletal muscle. IGSF1 is highly expressed in fetal liver, but is absent shortly after birth. In the adult testis, IGSF1 is present in Sertoli cells (epithelial stages XIII–VI), and elongating spermatids (stages X–XII). Specificity of protein expression was corroborated with Igsf1 mRNA expression in all tissues. The expression patterns of IGSF1 in the pituitary gland and testis are consistent with the pituitary hormone deficiencies and macroorchidism observed in patients with IGSF1 deficiency. The expression in the brain, adrenal gland, pancreas, liver, and muscle suggest IGSF1's function in endocrine physiology might be more extensive than previously considered.
